Macquarie Asset Management completed the acquisition of Genuone from IMM Private Equity for $449m.

Macquarie Asset Management, a global asset manager, completed the acquisition of Genuone, a pharmaceutical CDMO company, from IMM Private Equity, a holding company of leading Korean private capital management firms, for $449m. GeneOne Science is considered the number one domestic contract development and manufacturing organization for synthetic pharmaceuticals. It was launched by IMM PE in 2020 through the acquisition of Kolmar Korea Pharmaceutical Division and Kolmar Pharma.